Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027748 · ClinicalTrials.gov registry record · Phase 1
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
A Phase 1 study of Neuroblastoma and Refractory Neuroblastoma, sponsored by Steven DuBois, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT07027748 is a Phase 1 study of Neuroblastoma and Refractory Neuroblastoma that is actively recruiting participants, run by Steven DuBois, MD. The registered enrollment target is 18 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07027748, a Phase 1 study of Neuroblastoma and Refractory Neuroblastoma, is actively recruiting participants, sponsored by Steven DuBois, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study drugs involved in this study are: * Naxitamab (A type of monoclonal antibody) * Irinotecan (A standard of care chemotherapy) * Temozolomide (A standard of care chemotherapy) * Sargramostim (A standard of care, granulocyte-macrophage colony stimulating factor)
Conditions Studied
Interventions
- DRUG Naxitamab
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Sargramostim granulocyte-macrophage colony stimulating factor
Study Locations (2)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07027748
The ClinicalTrials.gov registry entry for NCT07027748 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The listed sponsor is Steven DuBois, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 4 interventions - of which Naxitamab is the first listed.
NCT07027748 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07027748 about?
NCT07027748 is a clinical study titled "Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma". This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study dru...
What is the current status of trial NCT07027748?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-06-27. Estimated completion is 2027-12-01.
What conditions does trial NCT07027748 study?
This clinical trial studies the following conditions: Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Neuroblastoma Recurrent.
What interventions are being tested in trial NCT07027748?
The interventions under investigation include: Naxitamab (DRUG), Temozolomide (DRUG), Irinotecan (DRUG), Sargramostim granulocyte-macrophage colony stimulating factor (DRUG).
Who is sponsoring clinical trial NCT07027748?
This trial is sponsored by Steven DuBois, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027748 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.